Pathology

Sushmita Sinha, PhD

Portrait

Research Assistant Professor of Pathology

Contact Information

Primary Office: 1132 Medical Laboratories
Iowa City, IA 52242
Primary Office Phone: 319-335-7601

Email: sushmita-sinha@uiowa.edu

Education

BSc, Biology, Dr. Bhim Rao Ambedkar University, Agra, India
MSc, Biotechnology, Dr. Bhim Rao Ambedkar University, Agra, India
PhD, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Junior Research Fellow, Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Senior Research Fellow, Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Research Summary

Explore immune-pathological and regulatory mechanisms of autoimmune diseases with particular emphasis on Multiple Sclerosis.

Selected Publications

Show All

Ayers C, Mendoza J, Sinha S, Cunnusamy K, Greenberg B, Frohman E, Karandikar N.  Modulation of Immune Function Occurs within Hours of Therapy Initiation for Multiple Sclerosis.  Clinical Immunology.  2013. 147(2):105-119.
[PubMed]

Offner H, Sinha S, Burrows G, Ferro A, Vandenbark A.  RTL therapy for multiple sclerosis: a Phase I clinical study.  Journal of Neuroimmunology.  2011. 231(1-2):7-14.
[PubMed]

Sinha S, Miller L, Subramanian S, Burrows G, Vandenbark  A, Offner H.  RTL551 treatment of EAE reduces CD226 and T-bet expressing CD4+ effector T-cells in the periphery and prevents infiltration of T-bet expressing and IL-17 and IFN-γ producing T-cells into the CNS.  PLoS One.  2011. 6(7):e21868.
[PubMed]

Sinha S, Miller L, Subramanian S, McCarty O, Proctor T, Romero R, Burrows G, Vandenbark A, Offner H.  Binding of T cell receptor ligands to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.  Journal of Neuroimmunology .  2010. 225(1-2):52-61.
[PubMed]

Sinha S, Prasad K, Jain D, Nyati K, Pradhan S, Agrawal S.  Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome.  Acta Neurologica Scandinavica .  2010. 122(1):21-26.
[PubMed]

Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows G, Grafe M, Linington C, Vandenbark A, Benard C, Offner H.  Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.  Journal of Neuroimmune Pharmacology .  2010. 5(2):231-239.
[PubMed]

Sinha S, Subramanian S, Miller L, Proctor T, Roberts C, Burrows G, Vandenbark A, Offner H.  Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in Experimental Autoimmune Encephalomyelitis by a single Recombinant T-Cell receptor Ligand.  Journal of Neuroscience .  2009. 29(12):3816-3823.
[PubMed]

Sinha S, Kaler L, Proctor T, Teuscher C, Vandenbark A, Hoffner H.  IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis.  Journal of Immunology .  2008. 180(4):2679-2685.
[PubMed]

Sinha S, Subramanian S, Proctor T, Kaler L, Grafe M, Dahan R, Huan J, Vandenbark A, Burrows G, Offner H.  A promising therapeutic approach for multiple sclerosis: Recombinant T-Cell Receptor Ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.  Journal of Neuroscience.  2007. 27(46):12531-12539.
[PubMed]

Sinha S, Prasad K, Jain D, Pandey C, Jha S, Pradham S.  Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.  Clinical Microbiology and Infection.  2007. 13(3):334-7.
[PubMed]

Date Last Modified: 07/31/2013 - 10:51:40